8-K: Envoy Medical Erases $32M Debt for $100K, CEO Taylor Resigns

Envoy Medical, Inc. has extinguished over $32 million in promissory note obligations for a one-time payment of $100,000, significantly strengthening its balance sheet, as its largest stockholder Glen Taylor resigns from the board.

Summary

• Envoy Medical, Inc. entered into a Satisfaction of Promissory Notes Agreement with GAT Funding, LLC, an entity controlled by its largest stockholder, Glen Taylor, on August 25, 2025.
• The agreement fully satisfied all obligations under three promissory notes issued to GAT Funding on February 27, 2024, August 27, 2024, and March 6, 2025.
• The total outstanding principal balance of these notes was $30,800,000, with accrued interest totaling $1,211,552, bringing the aggregate debt to $32,011,552.
• Envoy Medical paid GAT Funding $100,000 in cash to extinguish this entire debt.
• The Satisfaction Agreement was approved by the Company's Audit Committee, comprised of all independent directors, with Mr. Taylor not serving on the committee.
• Glen Taylor resigned from the Board of Directors, effective immediately, on August 25, 2025, citing a desire to focus on other business interests.
• The company stated that the extinguishment simplifies its capital structure, strengthens its financial foundation, and eliminates all term loan obligations without equity conversion.
• Envoy Medical plans to devote capital resources to the continued development of its lead product candidate, the investigational Acclaim cochlear implant.

Sentiment

Score: 9

Explanation: The sentiment is overwhelmingly positive due to the massive debt extinguishment for a minimal cash payment, which dramatically improves the company's financial health and future prospects. While the underlying reason for the discount (inability to pay) indicates past financial weakness, the resolution is a significant de-risking event. The ability to reallocate capital to product development further enhances the positive outlook.

Positives

• Extinguished over $32 million in principal and accrued interest for a payment of only $100,000, representing a massive debt reduction.
• Significantly strengthened the company's balance sheet and simplified its capital structure.
• Eliminated all term loan obligations without requiring equity conversion, avoiding dilution for existing shareholders.
• Allows the company to reallocate capital resources to the continued development of its lead product candidate, the Acclaim cochlear implant.
• The transaction was approved by an independent Audit Committee, indicating proper governance.

Negatives

• The company acknowledged a 'reasonable likelihood that the Company may be unable to pay the Notes in accordance with their terms,' indicating prior financial distress.
• The departure of Glen Taylor, a long-standing board member and the company's largest stockholder, could be seen as a loss of institutional knowledge or support, despite the stated reason for his resignation.

Risks

• Changes in the market price of shares of Class A Common Stock.
• Changes in or removal of the company's shares inclusion in any index.
• Success in retaining or recruiting, or changes required in, officers, key employees or directors.
• Unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of products.
• Competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices.
• Disruptions in relationships with suppliers, or disruptions in the company's own production capabilities for key components and materials.
• Changes in the need for capital and the availability of financing and capital to fund these needs.
• Changes in interest rates or rates of inflation.
• Legal, regulatory and other proceedings could be costly and time-consuming to defend.
• Changes in applicable laws or regulations, or the application thereof on the company.
• A loss of any of the company's key intellectual property rights or failure to adequately protect intellectual property rights.
• The effects of catastrophic events, including war, terrorism and other international conflicts.

Future Outlook

The company expects to devote its capital resources to the continued development of its lead product candidate, the investigational Acclaim cochlear implant, leveraging a stronger financial foundation. Management expresses confidence in the company's future and its ability to execute on its vision and drive shareholder value.

Management Comments

• "On behalf of the Envoy Medical board, we want to thank Glen Taylor for his years of service and his tremendous support of Envoy Medical over the years. With the extinguishment of the term loans, Envoy Medical has reset its balance sheet and we are now positioned to devote our capital resources to the continued development of our lead product candidate, the investigational Acclaim cochlear implant." Brent Lucas, Chief Executive Officer.
• "Our mission is to transform the hearing industry with groundbreaking, fully implanted technologies. With a stronger financial foundation, we are better equipped to deliver on that mission. We are deeply grateful for Glen Taylor’s unwavering belief in the Company—our fully implanted cochlear implant would not have been possible without his steadfast support." Brent Lucas, Chief Executive Officer.
• "It has been an honor to serve Envoy Medical and support its mission over nearly two decades. With the strong momentum in the Company’s pivotal clinical trial and the Company’s now improved financial position, I am retiring from the Envoy Medical board with great confidence in its future. I look forward to seeing all that Envoy Medical’s talented and passionate team will accomplish." Glen Taylor, Outgoing Chairman Emeritus.
• "While we will miss his contributions on the board, we also celebrate Glen’s legacy with Envoy Medical and wish him all the best. With a talented Board bringing more than 100 years of combined medical device experience, we are excited to execute on our vision and further drive shareholder value." Brent Lucas, Chief Executive Officer.

Industry Context

Envoy Medical operates in the hearing health industry, specializing in fully implanted hearing solutions. Its flagship products include the commercially available Esteem active middle ear implant and the investigational Acclaim cochlear implant, which received FDA Breakthrough Device Designation in 2019. The company aims to differentiate itself by leveraging natural ear anatomy for sound capture, rather than traditional microphones, addressing severe to profound sensorineural hearing loss. This debt extinguishment significantly improves its financial standing, allowing it to better compete and invest in R&D within the competitive medical device and hearing technology sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for the debt extinguishment transaction itself. However, it highlights its products: the Esteem FI-AMEI as the only FDA-approved, fully implanted hearing device for moderate to severe sensorineural hearing loss, and the Acclaim CI as a first-of-its-kind investigational device leveraging natural anatomy, which received FDA Breakthrough Device Designation in 2019. These product descriptions suggest a focus on innovation and unique technological approaches within the hearing solutions market, aiming to set new industry standards for fully implanted devices.

Management Changes

Corporate Governance

Related Party Transactions

• The Satisfaction of Promissory Notes Agreement was entered into with GAT Funding, LLC, an entity controlled by Glen Taylor, who was the company's largest stockholder and a board member (until his resignation). This constitutes a related-party transaction.

Stakeholder Impact

• **Shareholders:** Significant positive impact due to the elimination of over $32 million in debt for a minimal cash outlay, which substantially improves the company's balance sheet and reduces financial risk without equity dilution. This could lead to increased shareholder value.
• **Creditors (GAT Funding, LLC):** Accepted a highly discounted payment of $100,000 in full satisfaction of over $32 million in debt, while retaining rights to previously issued warrants. This represents a substantial loss on the debt but potentially preserves value through equity upside.
• **Employees:** A stronger financial foundation may provide greater job security and resources for product development, potentially fostering a more stable and innovative work environment.
• **Customers/Patients:** Improved financial stability allows the company to better focus on developing and bringing to market its innovative hearing solutions, potentially benefiting future patients with severe hearing loss.

Next Steps

• Continue the development of the investigational Acclaim cochlear implant.
• Execute on the company's vision to drive shareholder value with a strengthened financial foundation.

Key Dates

Recommendation

The extinguishment of over $32 million in debt for a mere $100,000 is a transformative event for Envoy Medical. While the underlying reason for the discount (the company's inability to pay) indicates past financial weakness, the *outcome* is a dramatically de-risked balance sheet. This move frees up capital for the development of its key product, the Acclaim cochlear implant, and significantly improves the company's long-term viability and financial flexibility. For a seasoned investor, this represents a substantial positive catalyst, potentially signaling a turning point for the company's financial health and growth prospects, making it a strong buy.

Keywords

Envoy Medical, COCH, Debt Extinguishment, Promissory Notes, GAT Funding, Glen Taylor, Board Resignation, Balance Sheet, Capital Structure, Acclaim Cochlear Implant, Medical Device, Hearing Health, SEC Filing, 8-K